Ionis Pharmaceuticals Inc (IONS) — Free Cash Flow Generation Index

Latest as of June 2025: 0.91x

Ionis Pharmaceuticals Inc (IONS) has a Free Cash Flow Generation Index of 0.91x as of June 2025. Free cash flow of $137.07 Million represents 1% of operating cash flow ($151.34 Million). See Ionis Pharmaceuticals Inc (IONS) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

FCF Generation Index

0.91x
Free Cash Flow / Operating CF

Free Cash Flow

$137.07 Million
USD

Operating Cash Flow

$151.34 Million
USD

Capital Expenditures

$14.27 Million
USD

Ionis Pharmaceuticals Inc Free Cash Flow Generation Index (2007–2021)

Historical FCF Generation Index trend for Ionis Pharmaceuticals Inc across 11 annual periods. Explore IONS cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Annual Free Cash Flow Generation for Ionis Pharmaceuticals Inc (2007–2021)

Year-by-year Free Cash Flow Generation Index for Ionis Pharmaceuticals Inc. For the full company profile including market capitalisation, see Ionis Pharmaceuticals Inc market capitalisation.

Year FCG Index Free Cash Flow (USD) Operating CF Capital Expenditures YoY Change
2021 0.42x $12.90 Million $30.80 Million $17.90 Million ▲ +391.5%
2020 -0.14x $-5.16 Million $35.89 Million $41.05 Million ▼ -116.0%
2019 0.90x $309.44 Million $345.72 Million $36.28 Million ▼ -7.8%
2018 0.97x $585.24 Million $602.89 Million $17.65 Million ▲ +24.0%
2017 0.78x $136.29 Million $174.15 Million $37.86 Million ▲ +76.3%
2015 0.44x $9.38 Million $21.12 Million $11.75 Million ▲ +157.9%
2014 -0.77x $-4.82 Million $6.29 Million $11.10 Million ▼ -183.7%
2013 0.92x $58.13 Million $63.49 Million $5.36 Million ▲ +152.1%
2012 -1.76x $-3.29 Million $1.88 Million $5.17 Million ▼ -291.0%
2008 0.92x $194.96 Million $212.03 Million $17.07 Million ▲ +6.8%
2007 0.86x $31.08 Million $36.09 Million $5.01 Million
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).